- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07283770
Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
A Phase 1 Study of VX-581 in Healthy Subjects and in Subjects With Cystic Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA in healthy participants. The study will also evaluate the safety, tolerability, and pharmacokinetics of VX-581 administered in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581 in healthy participants and in participants with CF. VX-581 will be administered alone and in combination with TEZ and D-IVA. The study consists of Screening Phase, Run-In Phase (CF only), Treatment Phase and Safety Follow-up Phase.
Note: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Medical Information
- Telefonnummer: 617-341-6777
- E-post: medicalinfo@vrtx.com
Studieorter
-
-
Kansas
-
Overland Park, Kansas, Förenta staterna, 66212
- Rekrytering
- Altasciences - Kansas City
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
-
Parts A, B, C:
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)
- A total body weight of more than (>) 50 kg
-
Part D:
- Confirmed diagnosis of CF
Key Exclusion Criteria:
-
Parts A, B, C:
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption
-
Part D:
- History of clinically significant cirrhosis with or without portal hypertension.
Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part A: Single Ascending Dose
Participants will be randomized to receive a single dose of VX-581. |
Suspension for Oral Administration. Tablets for Oral Administration. |
|
Placebo-jämförare: Placebo: Part A
Participants will be randomized to receive a single dose of placebo matched to VX-581. |
Suspension for Oral Administration. |
|
Experimentell: Part B: Multiple Ascending Dose
Participants will be randomized to receive multiple doses of VX-581. |
Suspension for Oral Administration. Tablets for Oral Administration. |
|
Placebo-jämförare: Placebo: Part B
Participants will be randomized to receive multiple doses of placebo matched to VX-581. |
Suspension for Oral Administration. |
|
Experimentell: Part C: VX-581 with TEZ/D-IVA or D-IVA
Participants will be randomized to receive multiple doses VX-581 in combination with TEZ/D-IVA or D-IVA. |
Suspension for Oral Administration. Tablets for Oral Administration. Tablet for Oral Administration.
Andra namn:
Tablet for Oral Administration.
Andra namn:
|
|
Placebo-jämförare: Placebo: Part C
Participants will be randomized to receive placebo matched to VX-581 in combination with TEZ/D-IVA or D-IVA. |
Suspension for Oral Administration. Tablet for Oral Administration.
Andra namn:
Tablet for Oral Administration.
Andra namn:
|
|
Experimentell: Part D: VX-581 with TEZ/D-IVA or D-IVA in CF
Participants with CF will enter a run-in period and receive ELX/TEZ/IVA. Following the run-in period participants will receive VX-581 in combination with TEZ/D-IVA or D-IVA in the treatment period. Following the treatment period, participants will enter a 14-day Washout Period and receive ELX/TEZ/IVA. (Part D will be open-label) |
Suspension for Oral Administration. Tablets for Oral Administration. Tablet for Oral Administration.
Andra namn:
Tablet for Oral Administration.
Andra namn:
Fixed dose combination (FDC) Tablets for Oral Administration.
Andra namn:
Tablet for Oral Administration.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From Day -1 up to Day 8
|
From Day -1 up to Day 8
|
|
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From Day -1 up to Day 17
|
From Day -1 up to Day 17
|
|
Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From Day -1 up to Day 17
|
From Day -1 up to Day 17
|
|
Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From Signing of Informed Consent up to Day 105
|
From Signing of Informed Consent up to Day 105
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-581
Tidsram: On Day 1
|
On Day 1
|
|
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Up to 24 Hours (AUC0-24h) Post-Dose of VX-581
Tidsram: On Day 1
|
On Day 1
|
|
Part B: Cmax of VX-581
Tidsram: On Days 1, 7, and 10
|
On Days 1, 7, and 10
|
|
Part B: AUC0-24h Post-Dose of VX-581
Tidsram: On Days 1, 7, and 10
|
On Days 1, 7, and 10
|
|
Part C: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Tidsram: On Days 1, 7, and 10
|
On Days 1, 7, and 10
|
|
Part C: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Tidsram: On Days 1, 7, and 10
|
On Days 1, 7, and 10
|
|
Part D: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Tidsram: On Day 1 and Day 28
|
On Day 1 and Day 28
|
|
Part D: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Tidsram: On Day 1 and Day 28
|
On Day 1 and Day 28
|
|
Part D: Absolute Change in Sweat Chloride (SwCl)
Tidsram: From Baseline Up To Day 28
|
From Baseline Up To Day 28
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Genetiska sjukdomar, medfödda
- Luftvägssjukdomar
- Matsmältningssystemets sjukdomar
- Lungsjukdomar
- Spädbarn, nyfödda, sjukdomar
- Bukspottkörtelsjukdomar
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Cystisk fibros
- ELEXACAFTOR, IVACAFTOR, Tezacaftor Drug Combination
- tezacaftor
- ivacaftor
- Deutivacaftor, Tezacaftor, Vanzacaftor
Andra studie-ID-nummer
- VX25-581-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .